Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (22443)	6/17/1998 11:59:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 32384

>> Eventually the street will recognize LGND's potential << An objective statement? At 3/31, shareholder's equity was $23 million. There were 38.6 million shares out. That figure would give us a market cap of $521 million at today's close, or a market cap:equity of 22.7. Henry.... what will the shareholder's equity be in the 6/30 figures? How many shares, fully-diluted, are outstanding? What would the market cap, fully-diluted, be at today's closing price? What will the approximate ratio of market cap to equity be, using these figures? Can you name some comparable ratios for other biotechs which do not have approved products? Hint..... the non-dilute ratio for EntreMed is about 8.1. For biotech's "sore thumb" with Rathman, Gates and a PDE5 inhibitor, Icos, it's about 17.8. What sort of recognition would you like the street to give LGND? Perhaps you have irrational expectations.